IN2014CN03610A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03610A
IN2014CN03610A IN3610CHN2014A IN2014CN03610A IN 2014CN03610 A IN2014CN03610 A IN 2014CN03610A IN 3610CHN2014 A IN3610CHN2014 A IN 3610CHN2014A IN 2014CN03610 A IN2014CN03610 A IN 2014CN03610A
Authority
IN
India
Prior art keywords
disease
treatment
condition
conditions
associated therewith
Prior art date
Application number
Other languages
English (en)
Inventor
Sasson Shmuel Ben
Arie Dagan
Sharon Perles
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of IN2014CN03610A publication Critical patent/IN2014CN03610A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
IN3610CHN2014 2011-11-15 2012-11-15 IN2014CN03610A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161559964P 2011-11-15 2011-11-15
US201261603508P 2012-02-27 2012-02-27
PCT/IL2012/050461 WO2013072915A1 (en) 2011-11-15 2012-11-15 Tricyclic compounds, compositions comprising them and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN03610A true IN2014CN03610A (enExample) 2015-10-09

Family

ID=48429067

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3610CHN2014 IN2014CN03610A (enExample) 2011-11-15 2012-11-15

Country Status (25)

Country Link
US (1) US9447040B2 (enExample)
EP (1) EP2802320B1 (enExample)
JP (1) JP6087367B2 (enExample)
KR (1) KR101986272B1 (enExample)
CN (1) CN104010636B (enExample)
AU (1) AU2012338362B2 (enExample)
BR (1) BR112014011641B1 (enExample)
CA (1) CA2855759C (enExample)
CL (1) CL2014001278A1 (enExample)
CO (1) CO7020909A2 (enExample)
DK (1) DK2802320T3 (enExample)
ES (1) ES2729713T3 (enExample)
HR (1) HRP20190927T1 (enExample)
HU (1) HUE043827T2 (enExample)
IN (1) IN2014CN03610A (enExample)
MX (1) MX347570B (enExample)
PE (1) PE20141940A1 (enExample)
PH (1) PH12014501061B1 (enExample)
PL (1) PL2802320T3 (enExample)
PT (1) PT2802320T (enExample)
RU (1) RU2624446C9 (enExample)
SG (1) SG11201402258UA (enExample)
SI (1) SI2802320T1 (enExample)
WO (1) WO2013072915A1 (enExample)
ZA (1) ZA201404065B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020919A1 (en) 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
EP4031130A4 (en) * 2019-09-15 2023-10-11 Raziel Therapeutics Ltd. COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS
AU2021213469B2 (en) * 2020-01-28 2026-06-04 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
WO2022058792A1 (en) * 2020-09-16 2022-03-24 Raziel Therapeutics Ltd. Compositions for the treatment of fat related conditions and disorders
EP4213835A4 (en) * 2020-09-16 2024-10-02 Raziel Therapeutics Ltd. COMPOSITIONS AND METHODS FOR TREATING LIPID-RELATED DISORDERS
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative
US20240335424A1 (en) * 2021-07-28 2024-10-10 Raziel Therapeutics Ltd. Compositions and methods for treating lipoma pain
CN115073374B (zh) * 2022-06-14 2023-10-27 五邑大学 一种α-葡萄糖苷酶抑制剂及其制备方法和应用
WO2024100533A1 (en) * 2022-11-07 2024-05-16 Raziel Therapeutics Ltd. Crystalline carbazole derivative and methods of making thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2590125A (en) * 1952-03-25 Quaternary-ammonium alkyl
US2676966A (en) * 1951-04-04 1954-04-27 Searle & Co Quaternary salts of 9-carbazolealkylamines and 10-acridanalkylamines and methods forpreparing same
US2676971A (en) * 1951-04-21 1954-04-27 Searle & Co Quaternary ammonium derivatives of aminoalkylxanthenes and aminoalkylthiaxanthenes
FR1186832A (fr) 1956-08-03 1959-09-02 Etablissements Clin-Byla Composés hétérocycliques dérivés du pyrrol et des benzopyrrols et leur fabrication
GB832568A (en) 1956-08-03 1960-04-13 Clin Byla Ets Heterocyclic compounds and production thereof
US2930798A (en) * 1956-08-03 1960-03-29 Clin Byla Ets 3-alkanoyl 1-tertiary-amino-alkyl indol oximes and production thereof
GB866418A (en) * 1958-01-25 1961-04-26 Bayer Ag Phenoxazine derivatives
US3836587A (en) * 1969-11-17 1974-09-17 American Cyanamid Co Organo phosphonium salts
AR205331A1 (es) * 1972-07-24 1976-04-30 Hoffmann La Roche Procedimiento para la preparacion de carbazoles
FR2691459B1 (fr) * 1992-05-25 1995-06-09 Adir Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH11504905A (ja) 1995-05-05 1999-05-11 ノボ ノルディスク アクティーゼルスカブ 新規複素環の化学
US6440961B1 (en) * 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
GB9925880D0 (en) 1999-11-01 1999-12-29 British Tech Group Int B-Carboline derivatives
DE60218155D1 (de) 2001-03-28 2007-03-29 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
WO2003027084A1 (en) 2001-09-25 2003-04-03 Dr. Reddy's Laboratories Ltd. Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents
US7428091B2 (en) * 2004-11-15 2008-09-23 Gentex Corporation Electrochromic compounds and associated media and devices
US20070213359A1 (en) 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
US20090317372A1 (en) * 2008-06-20 2009-12-24 Zoltan Kiss Small molecules for the reduction of high blood glucose level
UA107652C2 (en) * 2008-10-06 2015-02-10 Incuron Llc Carbazole compounds and therapeutic uses of the compounds
CA2748813C (en) * 2009-01-09 2018-07-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9095572B2 (en) * 2009-01-09 2015-08-04 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds

Also Published As

Publication number Publication date
PE20141940A1 (es) 2014-12-18
RU2014119711A (ru) 2015-12-27
HUE043827T2 (hu) 2019-09-30
SI2802320T1 (sl) 2019-08-30
PH12014501061B1 (en) 2018-12-12
CN104010636A (zh) 2014-08-27
HRP20190927T1 (hr) 2019-08-23
WO2013072915A1 (en) 2013-05-23
MX347570B (es) 2017-05-02
MX2014005765A (es) 2015-09-23
US20140329877A1 (en) 2014-11-06
AU2012338362B2 (en) 2017-05-18
PH12014501061A1 (en) 2014-06-23
EP2802320A1 (en) 2014-11-19
BR112014011641B1 (pt) 2020-10-27
EP2802320B1 (en) 2019-02-20
BR112014011641A2 (pt) 2017-05-02
JP2014533264A (ja) 2014-12-11
CO7020909A2 (es) 2014-08-11
US9447040B2 (en) 2016-09-20
AU2012338362A1 (en) 2014-05-29
CA2855759A1 (en) 2013-05-23
JP6087367B2 (ja) 2017-03-01
EP2802320A4 (en) 2015-08-12
CA2855759C (en) 2020-03-10
RU2624446C9 (ru) 2018-04-04
PT2802320T (pt) 2019-06-17
CL2014001278A1 (es) 2014-12-26
ZA201404065B (en) 2015-11-25
SG11201402258UA (en) 2014-06-27
DK2802320T3 (da) 2019-05-27
CN104010636B (zh) 2017-04-12
ES2729713T3 (es) 2019-11-05
PL2802320T3 (pl) 2019-09-30
KR20140099492A (ko) 2014-08-12
RU2624446C2 (ru) 2017-07-04
KR101986272B1 (ko) 2019-06-05

Similar Documents

Publication Publication Date Title
PH12014501061B1 (en) Tricyclic compounds, compositions comprising them and uses thereof
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
BR112012022755A2 (pt) composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos
TN2015000278A1 (en) Autotaxin inhibitors
IN2015DN01197A (enExample)
PL2898061T3 (pl) Kompozycje probiotyczne do leczenia otyłości i stanów związanych z otyłością
CR20120202A (es) Métodos y composiciones para tratar cáncer
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
MX361233B (es) Inhibidores de hsp90 c-terminales.
IN2015DN01161A (enExample)
SG179161A1 (en) Tricyclic compounds and pharmaceutical uses thereof
NZ708727A (en) Conjugate compounds
MX351368B (es) Compuestos heteroarilo y metodos para utilizarlos.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
WO2013045404A3 (de) Inhibition von interleukin 1 beta zur behandlung der endometriose
MX355915B (es) Moduladores del receptor de androgenos y usos de los mismos.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
NZ702239A (en) Heteroaryl compounds and methods of use thereof
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.